Communiqués NextCell Pharma AB

Actions

NXTCL

SE0009723125

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:31 31/05/2024			Varia. 5j.	Varia. 1 janv.
1,515 ^SEK	-23,10%		+2,02%	-42,40%

27/05	Nextcell Pharma AB élit Hans-Peter Ekre comme nouveau président du conseil d'administration	CI
25/04	NextCell Pharma AB présente ses résultats pour le deuxième trimestre et les six mois terminés le 29 février 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

The subscription period in NextCell's rights issue commences today	31/05	AQ
NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million	30/05	AQ
Single treatment with ProTrans demonstrates long-term therapeutic effect over 5 years	28/05	AQ
Bulletin from the Extraordinary General Meeting of NextCell Pharma AB (publ)	27/05	AQ
NextCell publishes its Interim Report 2 2023/2024	25/04	AQ
Notice of Extraordinary General Meeting in NextCell Pharma AB (publ)	24/04	AQ
The Board of Directors of NextCell resolves on a rights issue of units of approximately SEK 40.1 million, subject to approval by an Extraordinary General Meeting	24/04	AQ
NextCell's daughter company Cellaviva granted permission to handle amniotic tissue	22/04	AQ
Anders Essen-Möller resigns as Chairman of the Board of Directors due to health reasons	19/04	AQ
The Swedish Medical Products Agency approves subgroup analysis in NextCell's ProTrans-Young study	27/03	AQ
NextCell establishes QVance to meet the Nordic's need for quality analytics	14/03	AQ
NextCell Pharma's updated growth strategy	27/02	AQ
NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy	14/02	AQ
NextCell publishes its Interim Report 1 2023/2024	25/01	AQ
Updates regarding NextCell's Clinical Trials with ProTrans	24/01	AQ
NextCell Pharma has compiled a Q&A section	13/12	AQ
Repeated treatment with ProTrans is immunologically safe	06/11	AQ
NextCell publishes its Year-End Report 2022/2023	26/10/23	AQ
NextCell signs an agreement for a new tissue product	10/10/23	AQ
NextCell Pharma presents at the Advanced Therapies Europe conference	05/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués NextCell Pharma AB

Actions

NXTCL

SE0009723125

Communiqués

Filtres